HBV: the same than HCV?

Size: px
Start display at page:

Download "HBV: the same than HCV?"

Transcription

1 HBV: the same than HCV? Maurizia Rossana Brunetto UO Epatologia - Azienda Ospedaliero Universitaria Pisana Centro Riferimento Regionale - Diagnosi e trattamento delle epatopatie croniche e del tumore di fegato

2 A personalized approach to the management of chronic hepatitis C in women requires a careful evaluation of liver disease stage and activity according to age, co-factors of liver disease and personal needs

3 Impact of Gender, Viral transmission and Aging in the prevalence of HBsAg Tsay P-W, Chang Gung Med J 2009 Gender differences in prevalence of HBsAg and anti-hcv in individuals receiving a general check-up in Taiwan. The prevalence of HBsAg was higher in men than in women (p<0.001) especially for those younger than 60 years.

4 Gender and HBV infection The long term serological course of asymptomatic HBV carriers and development of HCC Alward WL, J Infect Dis 1985 In a cohort of 150 asymptomatic carriers during a mean f.u. 6.1 years, both HBeAg/anti-HBe seroconversion and HBsAg clearance occurred more frequently in female than male ( p <0.01 and 0.02 respectively) Incidence and determinants of spontaneous seroclearance of HBeAg and DNA in patients with CHB Yang H-I, Clin Gastroent. and Hepatol 2012 In a cohort of 1289 HBV carriers, 439 of whom HBeAg positive, the factors influencing HBeAg/anti-HBe seroconversion were female sex (p=0.002), genotype B (p<0.001), pre-core 1896 (p=0.043), baseline ALT and HBV- DNA. Female sex, on the contrary, did not influence the HBV-DNA clearance

5 Gender and HBV infection HBeAg to anti-hbe seroconversion occurs at higher rates in females as compared to males Predictors associated with a nonresponse to HBV vaccination include male sex, older age, obesity and immunocompromising chronic diseases Estradiol induces the production of IFNγ in lymphocytes Estradiol augments an antigen-specific primary antibody response in PBMC

6 Chronic HBV infection profile in a single center cohort UO Epatologia - Pisa 516 chronic HBV carriers 163 females 353 males (31.6%) (68.4%) Brunetto MR, Roma y Mean age 51.2 y p=n.s 7.4% HBeAg pos/anti-hbe 15.1% p=0.021 Liver disease No/Yes 49.7%/50.3% 34%/66.8% p= % HCC 6.2% p=0.05

7 Chronic HBV infection profile in a single center cohort UO Epatologia - Pisa 511 chronic HBV carriers 161 females 350 males (31.6%) Inactive Carriers (68.4%) 56 (39.7%) (60.2%) Active Carriers HBV-DNA <20000 IU/ml 23 (41.8%) 32 (58.2%) 55 Active Carriers 57 (29.1%) 139 (70.9%) HBV-DNA >20000 IU/ml 196 Cirrhosis (21%) 94 (79%) Chi , p =0.003 Brunetto MR, Roma 2012

8 Presence/absence of Chronic Hepatitis B by gender and age N. of patients Age (by decades) Brunetto MR, Roma 2012

9 Prevalence of Cirrhosis by age Age years Prevalence Variation Eemales Males Prevalence Variation <30 0/8 0/ /31 (3.2%) 3/56 (5.4%) /43 (7.0%) 8/72 (11.1%) /38 (7.9%) 25/96 (26.0%) 4.5 x /27 (37%) 38/75 (50.7%) 1.3 x /16 (50%) 20/28 (71.4%) 2.5 x 2 x 1.4 x Brunetto MR, Roma 2012

10 Male to female ratio between 2 age groups of HBV related HCC 901 Japanese patients 32.8% P< % Tanaka Y et al, J Hepatol 2006

11 HCC incidence is 5 to 7-fold higher in males than females Androgens Higher activities of androgen axis correlate with a higher risk of HCC HBx protein enhances the transcriptional activity of the androgen receptor in an androgen concentration dependent manner Wu J-F et al, Gastroenterology 2010 Androgen and its receptor enhance HBV replication in transgenic mice Tian Y et al, J Virol 2012 Estrogens Estrogens can repress transcription of HBV genes by up-regulating ER-α which interacts with and alters the binding of HNF-4 α to the HBV enhancer 1 This could account for lower viral load and reduced incidence of HCC in women Wang S-H et al, Gastroenterology 2012

12 than a man? Better to be a woman

13 Hepatology Unit University Hospital - Pisa, Italy Antonella Cristofani Simonetta Ferretti (part-time) Simona Giannetti Teresa Crisponi (part-time) Isabella Rossi (Chief) Nurses Pietro Ciccorossi Barbara Coco Piero Colombatto Filippo Oliveri Veronica Romagnoli Carlotta Rastelli Beatrice Cherubini Medical Doctors Administrative Personel Arianna Del Chicca Biologists Daniela Cavallone Francesco Moriconi Angela Stabile Bio-Physics Luigi Civitano Ranieri Bizzarri Ferruccio Bonino Gatroenterology Chair Pisa University

Il Virus: categorie virologiche e stadiazione

Il Virus: categorie virologiche e stadiazione Il Virus: categorie virologiche e stadiazione Maurizia Rossana Brunetto UO Epatologia Azienda Ospedaliero Universitaria Pisana - Centro Riferimento Regionale Diagnosi e trattamento delle epatopatie croniche

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

Currently, hepatitis B e antigen (HBeAg)-negative hepatitis

Currently, hepatitis B e antigen (HBeAg)-negative hepatitis GASTROENTEROLOGY 2010;139:483 490 Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers MAURIZIA ROSSANA BRUNETTO,* FILIPPO OLIVERI,* PIERO

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013 Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

NATURAL HISTORY OF HEPATITIS B

NATURAL HISTORY OF HEPATITIS B NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical

More information

Chronic hepatitis B (CHB) infection is a large

Chronic hepatitis B (CHB) infection is a large AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

More information

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?

More information

HBsAg Quantification: Should It be Part of The Treatment Algorithm for CHB? Stephen N. Wong, MD

HBsAg Quantification: Should It be Part of The Treatment Algorithm for CHB? Stephen N. Wong, MD HBsAg Quantification: Should It be Part of The Treatment Algorithm for CHB? Stephen N. Wong, MD Outline How will HBsAg quantification affect threshold for treatment? Does it influence probability of complications?

More information

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,

More information

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe

More information

Hepatitis B virus (HBV) infection is a global

Hepatitis B virus (HBV) infection is a global VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung

More information

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients Hepatol Int (2013) 7:88 97 DOI 10.1007/s12072-012-9343-x ORIGINAL ARTICLE Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative

More information

Treatment of chronic hepatitis B 2013 update

Treatment of chronic hepatitis B 2013 update 22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical

More information

What have we learned from HBV clinical cohorts?

What have we learned from HBV clinical cohorts? PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

HEPATITIS B: WHO AND WHEN TO TREAT?

HEPATITIS B: WHO AND WHEN TO TREAT? HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues

More information

4th International HIV/Viral Hepatitis Co-Infection Meeting

4th International HIV/Viral Hepatitis Co-Infection Meeting 4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings

More information

Epidemiology of hepatitis B and D in Greece

Epidemiology of hepatitis B and D in Greece Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections

More information

Hepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital

Hepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Hepatitis B virus infection Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Chronic Hepatitis B - are we in the same situation as hepatitis C? Treatment of chronic hepatitis

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

Occult Hepatitis B Infection: why, who and what to do?

Occult Hepatitis B Infection: why, who and what to do? Occult Hepatitis B Infection: why, who and what to do? MF Yuen, MD, PhD Chair of Gastroenterology and Hepatology Department of Medicine The University of Hong Kong Queen Mary Hospital, Hong Kong Who? Different

More information

Chronic Hepatitis B Infection

Chronic Hepatitis B Infection Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis

More information

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and

More information

Chronic Hepatitis B: management update.

Chronic Hepatitis B: management update. Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Hepatitis B. Epidemiology and Natural History and Implications for Treatment Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco

More information

The Hepatitis B-e antigen-positive

The Hepatitis B-e antigen-positive The Hepatitis B-e antigen-positive Dental Student Developing an Equitable Policy Hepatitis B Virus Serology 1 HBsAg A protein on the surface of HBV; it can be detected in high levels in serum during acute

More information

Don t interfere My first choice is always nucs!

Don t interfere My first choice is always nucs! Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr

More information

Bible Class: Hepatitis B Virus Infection

Bible Class: Hepatitis B Virus Infection Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:

More information

2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B

2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations

More information

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,

More information

Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B 699 HEPATITIS Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B F Bonino, P Marcellin, G K K Lau, S Hadziyannis, R Jin, T Piratvisuth, G

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Title Author(s) Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Bonino, F; Marcellin, P; Lau, GKK; Hadziyannis, S; Jin, R; Piratvisuth,

More information

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute

More information

How to use pegylated Interferon for Chronic Hepatitis B in 2015

How to use pegylated Interferon for Chronic Hepatitis B in 2015 How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE

More information

MedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article

MedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic

More information

Seroclearance of the hepatitis B surface antigen

Seroclearance of the hepatitis B surface antigen A Large Case-Control Study on the Predictability of Hepatitis B Surface Antigen Levels Three Years Before Hepatitis B Surface Antigen Seroclearance Wai-Kay Seto, 1 Danny Ka-Ho Wong, 1 James Fung, 1 Ivan

More information

coinfected patients predicts HBsAg clearance during long term exposure to tenofovir

coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia

More information

Management of Hepatitis B - Information for primary care providers

Management of Hepatitis B - Information for primary care providers Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut Online First, published on November 24, 2006 as 10.1136/gut.2005.089722 1 Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Authors:

More information

HBV in HIV Forgotten but not Gone

HBV in HIV Forgotten but not Gone Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives

More information

Hepatitis B: is there still a role for interferon?

Hepatitis B: is there still a role for interferon? 16 January 2018 Hepatitis B: is there still a role for interferon? Pietro Lampertico Gastroenterology and Hepatology Division Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of Milan

More information

Maitines septiembre de 2011 Francisco Jorquera Plaza

Maitines septiembre de 2011 Francisco Jorquera Plaza Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas

More information

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite

More information

Hepatitis B and D Update on clinical aspects

Hepatitis B and D Update on clinical aspects Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy

More information

Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri

Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri Nicola Coppola Dipartimento di Salute Mentale e Medicina Preventiva Seconda Università di Napoli Main goal of treatment of chronic

More information

Steatosi epatica ed HCV

Steatosi epatica ed HCV Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:

More information

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection Tung-Hung Su 1,2,3, Chun-Jen Liu 1,2,3, Tai-Chung Tseng 2,4, Chen-Hua Liu 1,2,3, Hung-Chih Yang 1,5, Chi- Ling Chen

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Original Article. Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing , China 2

Original Article. Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing , China 2 Original Article Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha 2a Treatment Ming Hui Li 1,

More information

Management of Chronic Hepatitis B in Asian Americans

Management of Chronic Hepatitis B in Asian Americans Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,

More information

APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College

APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for

More information

ARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update

ARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies Y. Xiang*, P. Chen*,

More information

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers

More information

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated

More information

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History

More information

An Update HBV Treatment

An Update HBV Treatment An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard

More information

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015 THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook

More information

Clinical Case Maria Butí, MD, PhD

Clinical Case Maria Butí, MD, PhD Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with

More information

Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection

Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?

More information

Hepatitis B Diagnosis and Management. Marion Peters University of California San Francisco

Hepatitis B Diagnosis and Management. Marion Peters University of California San Francisco Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage

More information

Short title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract

Short title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract A Multicenter, prospective, Non-Interventional Study Evaluating Response Parameters during and after Therapy with PEGASYS (Peginterferon alfa-2a 40KD) in Subjects with HBeAg positive or HBeAg negative

More information

Mortality from viral hepatitis in the Netherlands. S.W. Schalm & M.Toy. Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL

Mortality from viral hepatitis in the Netherlands. S.W. Schalm & M.Toy. Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL Mortality from viral hepatitis in the Netherlands S.W. Schalm & M.Toy Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL Burden of disease: chronic viral hepatitis in NL annual

More information

New therapeutic perspectives in HBV: when to stop NAs

New therapeutic perspectives in HBV: when to stop NAs Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,

More information

Multicenter evaluation of the Elecsys HBsAg II quant assay

Multicenter evaluation of the Elecsys HBsAg II quant assay CVI Accepts, published online ahead of print on 31 August 2011 Clin. Vaccine Immunol. doi:10.1128/cvi.05122-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Chronic hepatitis B virus (HBV) infection remains a major

Chronic hepatitis B virus (HBV) infection remains a major CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Professor Vincent Soriano

Professor Vincent Soriano Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,

More information

HBV Diagnosis and Treatment

HBV Diagnosis and Treatment HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA

More information

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection xxxxxxxxxxxxxxx Özgür Günal 1, Şener Barut 1, İlker Etikan 2, Fazilet Duygu 1, Umut Tuncel 3, Mustafa

More information

Hepatitis B: Future treatment developments

Hepatitis B: Future treatment developments Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main

More information

Chronic infection with hepatitis B virus (HBV) is still a

Chronic infection with hepatitis B virus (HBV) is still a CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:527 534 Incidence and Determinants of Spontaneous Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B HWAI I YANG,*,, HSIU LIAN HUNG, MEI

More information

During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B

During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Yao-Shih Hsu, 1 Rong-Nan Chien, 1 Chau-Ting Yeh, 1 I-Shyan Sheen, 1 Hung-Yi Chiou, 2 Chia-Ming Chu, 1 and Yun-Fan

More information

NUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.

NUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from

More information

Long-Term Follow-Up of Hepatitis B e Antigen- Negative Hepatitis B Virus Carriers according to the Status of HBV DNA and ALT Levels -

Long-Term Follow-Up of Hepatitis B e Antigen- Negative Hepatitis B Virus Carriers according to the Status of HBV DNA and ALT Levels - International Journal of Hepatology & Gastroenterology Research Article Long-Term Follow-Up of Hepatitis B e Antigen- Negative Hepatitis B Virus Carriers according to the Status of HBV DNA and ALT Levels

More information

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases Viruses in July (ViJ), 2004 Overview Epidemiology Perinatal transmission

More information

DNA 2 91% (185/203), 82% (75/91), 75% (47/63), 62% (26/42) 200,000, 20, ,999, 2,000-19,999, <2,000 ( P

DNA 2 91% (185/203), 82% (75/91), 75% (47/63), 62% (26/42) 200,000, 20, ,999, 2,000-19,999, <2,000 ( P Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen Negative Chronic Hepatitis B Virus Infection? George V. Papatheodoridis, 1 Emanuel K. Manesis,

More information

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,

More information

Hepatitis B screening and surveillance in primary care

Hepatitis B screening and surveillance in primary care Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures

More information

(2016), «EUREKA: Health Sciences» Number 6

(2016), «EUREKA: Health Sciences» Number 6 THE SERUM CONCENTRATION OF HBSAG IN PATIETS WITH CHB/HIV CO-INFECTION COMPARING WITH CHB MONO-INFECTION IN THE DIFFERENT PHASES OF NATURAL COURSE OF CHRONIC HEPATITIS В Larisa Moroz Department of Infectious

More information

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High

More information

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,

More information

Acute Hepatitis B Virus Infection with Recovery

Acute Hepatitis B Virus Infection with Recovery Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis

More information

Hepatitis B Treatment Pearls. Agenda

Hepatitis B Treatment Pearls. Agenda Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,

More information

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis

More information

HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But

HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,

More information